Malignant transformation of cells does not necessarily abrogate their potential for expression of differentiated characteristics, including cessation of proliferation. 23, 37 Spontaneous differentiation of medulloblastoma to a nonproliferative state occasionally does occur, 11 indicating that neuroectodermal features and the current lack of sufficiently effective therapeutic strategies make agents that may induce differentiation of these tumor particularly interesting.
Phenylacetate (PA) is a naturally occurring plasma component, produced in the ␤ oxidation of fatty acids. It has in vitro differentiating activity for HL-60 promyelocytic leukemia cells 32 and is capable of inducing fetal hemoglobin production in K-562 erythroleukemia cells. 12, 33 In addition, it induces differentiation in prostate cancer cells. 34 In primates, PA is conjugated to glutamine, yielding phenylacetylglutamine, and has been used to relieve hyperammonemia in infants with urea cycle abnormalities. 4 That clinical experience documented the safety of doses that produce levels in the 3 to 6 mm range, and plasma levels as high as 19 mM were not found to be fatal Inhibition of proliferation and induction of differentiation in medulloblastoma-and astrocytoma-derived cell lines with phenylacetate (SW Brusilow, personal communication, 1992) . Because PA demonstrates growth inhibitory and differentiating effects in vitro at plasma levels in the 6-to 10-mM range, it seems probable that therapeutically effective doses can be administered to humans without unacceptable toxicity.
The mechanisms by which differentiating agents affect the growth and phenotypical characteristics of responsive cell lines have been studied extensively and, although their actions are incompletely understood, a substantial body of evidence indicates that agents such as alltransretinoic acid (ATRA) interact with autocrine growth control pathways. 13, 40 A variety of growth factor molecules and their receptors are affected by exposure to differentiating agents such as ATRA. In a number of neoplastic cell lines, as well as in nonneoplastic cell types, ATRA induces production and secretion of one or more isoforms of transforming growth factor (TGF)-␤. 13, 40 The TGF␤ autocrine growth regulatory pathways are of particular interest in primary CNS tumors. The pluripotential growth regulator is produced both by primary malignant astrocytoma tissue 7, 36 and by cell lines derived from such tumors. 19 The immunosuppressive effects of malignant astrocytoma cells on cocultured lymphocytes in vitro have been convincingly linked to TGF␤ production and can be partially neutralized by antibodies against TGF␤. 39 Transforming growth factor-␤ has been shown to be a growth regulator for gliomas in vitro. 19 The role of the TGF␤ pathway in growth regulation of medulloblastoma is less well established than for malignant astrocytomas. We have found that the antiproliferative effect of ATRA on Daoy medulloblastoma cells is associated with increased secretion of TGF␤ and with induction of TGF␤ receptor expression (FS Lieberman, unpublished data).
To define the capability of PA to inhibit growth and induce differentiation in neuroectodermal tumor cell lines, we studied the effects of PA in two human medulloblastoma cell lines (Daoy and D283 MED) as well as in one human (U-251MG) and two rodent (C6 and RG2) cell lines of glial origin. The effects of PA on these cell lines were compared to the human neuroblastoma cell line BE(2)C because this cell line represents a well-characterized bidirectional differentiation model for neuronal and schwann/glial cell differentiation. 3, 6, 29, 30 
Materials and Methods

Cell Culture Techniques
Human glioma (U-251MG), rat glioma (C6 and RG2), human medulloblastoma (Daoy and D283 MED), human neuroblastoma (BE(2)C), and the murine lung fibroblast cell line Mu1Lv were routinely maintained in Eagle's minimal essential medium (MEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), nonessential amino acids, L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 g/ml). Adherent cell lines were plated in T-150 tissue-culture flasks and passaged using trypsinization when the cells were 70% confluent. The cell line growing in suspension (D283 MED) was maintained at a cell density of 10 5 to 10 6 cells/ml. Cells were grown at 37˚C in an incubator humidified with 5% CO 2 . For glutamine depletion studies, U-251MG cells were adapted to serum-and glutamine-free Ultraculture medium. For proliferation studies with exogenous TGF␤ 1 and TGF␤ 2 and neutralizing antibodies against TGF␤, Daoy cells were grown in MEM containing 0.2% FCS, and U-251MG cells were cultured in serumfree Ultraculture medium.
Phenylacetic Acid Treatment of Cell Lines
Phenylacetic acid was dissolved in MEM to make a 100-mM stock solution and the pH was adjusted to 7.2 with NaOH. The MEM was then supplemented with 10% FCS.
Cell Proliferation Assay
For proliferation studies, tumor cells in log-phase growth were harvested and resuspended at a concentration of 20,000 cell/ml; 100 l/well of the cell suspension was placed into 96-well microtiter plates. After 24 hours the cells were incubated with an equal volume of serial dilutions of PA to yield final concentrations ranging from 2.5 to 20 mM. The MEM containing 10% FCS served as a control. Cell proliferation was determined at 24-hour intervals by [ 3 H]thymidine incorporation. One microCurie of [ 3 H]thymidine was added to each well, and the microtiter plates were incubated for 4 hours at 37˚C. Cells were then harvested onto glass-fiber filters using a semiautomated cell harvester, and [ 3 H]thymidine activity was quantitated using a liquid scintillation counter. All data points were obtained in quadruplicate. 
Measurement of Effects of Exogenous TGF␤
Washout Studies
Cells were seeded similarly to proliferation studies but at a concentration of only 250 cells/well. Two days after treatment with PA at various concentrations, the medium containing the PA was replaced by plain culture medium and [ 
Immunocytochemical Studies
Adherent cell lines were grown on eight-chamber slides for 24 hours under the same conditions previously described for cell cultures in culture flasks. Cells were then treated with 20, 10, or 5 mM PA for 4 to 7 days. After fixation in cold acetone, immunoreactivity was determined using the avidin-biotin-peroxidase complex method of Hsu, et al. 16 For nonadherent cell lines, cytocentrifuged preparations were made.
Mouse monoclonal antibodies (mAbs) specific against glial fibrillary acidic protein (GFAP), neurofilament (NF)-triplet proteins (NFL-L, 68 kD; NF-M, 160 kD; and NF-H, 200 kD), synaptophysin, or vimentin were used in these studies as well as anti-TGF␣ and epidermal growth factor receptor (EGFR) antibodies, and antihuman leukocyte antigens (HLAs) class I and II mAbs. An irrelevant mouse mAb (MOPC-21) served as a negative control.
Anti-Hu immunoglobin (Ig)G was prepared from a high-titer anti-Hu serum and conjugated to biotin as reported previously. 41 Frozen sections (7 m thick) of human brain served as a positive tissue control. Biotinylated IgG from normal human serum served as a negative control.
Western Blotting
Tumor cells were solubilized in 50 mM Tris-HCl, pH 7.2, containing 0.5% NP-40 and protease inhibitors (Cocktail 1 = phenylmethylsulfonylfluoride (1 mM), pepstatin (1 g/ml), leupeptin (1 g/ml), soybean trypsin inhibitor (1 g/ml), aprotinin (1 g/ml), and benzamidine (5 g/ml). Equal aliquots of the protein extracts were electrophoresed on 8% or 10% sodium dodecylsulfate (SDS)-polyacrylamide gels under denaturing conditions. The proteins were then electroblotted from the gel onto 0.2-m pore-sized nitrocellulose. Blots were blocked in 5% milk for 2 hours and incubated with the appropriately diluted primary antibody (mAb in mouse or human anti-Hu antiserum) for 1 hour. Blots were then incubated for 1 hour with appropriately diluted horseradish peroxidase-conjugated sheep anti-IgG directed against the appropriate species of primary antibody. Immunoreactivity was then detected using a chemiluminescent kit. Irrelevant murine mAb and normal human sera served as negative controls.
Cell Cycle Analysis
For cell cycle studies, Daoy cells were plated in T-150 culture flasks in serum-containing medium. After 24 hours of incubation, the culture medium was replaced by serum-free Ultraculture medium for 24 hours to synchronize the cell cultures; the cultures were then refed medium containing 10 mM PA or plain serum-containing medium. Cells were harvested after 48 hours, stained with acridine orange, and analyzed on a FACS scan.
Reverse Transcriptase-Polymerase Chain Reaction Assay of Hu Expression
Total RNA (1 g) from tumor cell lines was reverse transcribed with random hexamers (2.5 M) for 50 minutes at 37˚C in a reaction volume of 20 l containing the following: 1 mM each deoxynucleoside triphosphate (dNTP), 1 U/l RNAase inhibitor, and 2.5 U/l reverse transcribed Moloney murine leukemia virus. Reverse transcriptase (RT) reactions were terminated by incubation at 99˚C for 5 minutes. One-twentieth of the RT reaction product was used for polymerase chain reaction (PCR) amplification. Polymerase chain reaction was performed in a 1 ϫ PCR buffer (50 mM Tris, pH 9.5; 1.5 mM MgCl 2 , 20 mM ammonium sulfate), 0.2 mM each dNTP, 5 Ci of [ 
Enzyme-Linked Immunosorbent Assay for TGF␤ 2
Conditioned medium was concentrated 20-fold using Centriprep concentrators to a final volume of 20 l. All the concentration steps were performed at 4˚C. Protease inhibitors (Cocktail 1) were added to the concentrated samples prior to storage at Ϫ70˚C. Latent TGF␤ was activated by adding glacial acetic acid to the samples to yield a final concentration of 1 M acetic acid. Then the samples were evaporated to dryness using a speed vacuum and redissolved in 200 l distilled water. The reconstitution/drying step was repeated for a total of three washes. Samples were then redissolved in the sample treatment buffer RD5B provided in the Quantikine TGF␤ 2 kit and the capture enzyme-linked immunosorbent assay (ELISA) protocol was performed following the manufacturer's instructions. All data points were obtained in duplicate. The colorimetric reaction was quantitated by measuring absorbance at 540 nm using a microplate reader and Elisamatic software. A standard curve was generated using human recombinant TGF␤ 2 as the protein standard.
Sources of Supplies and Equipment
The U-251MG, C6, RG2, Daoy, D283 MED, and BE (2) The cell harvester used in the cell proliferation assay was obtained from Cambridge Biotechnologies, Watertown, MA; the liquid scintillation counter was manufactured by Hewlett-Packard, Downers Grove, IL. The Cytospin II, available from Shandon, Pittsburgh, PA, was used to cytocentrifuge cells for the immunocytochemical studies. Becton Dickinson provided the FACScan used in the cell cycle analysis. The PCR analysis was performed using a Perkin-Elmer-Cetus DNA cycler.
In the ELISA for TGF␤ 2 , we used Centriprep concentrators from Amico, Beverly, MA, and the Quantikin TGF␤ 2 kit obtained from R&D Systems. Bio-Rad (Richmond, CA) provided both the microplate reader and the Elisamatic software.
Results
Effects of PA on Cell Growth and Cell Cycle
All six cell lines showed a dose-dependent growth inhibition after incubation with PA ( Fig. 1 left) with a maximum effect after 48 to 96 hours. The human malignant glioma cell line U-251MG, which was previously reported to be ATRA resistant, 48 also responded to PA. The human tumor cell lines as well as the rat glioma cell line C6 showed median inhibitory concentration (IC 50 ) values for PA between 5.8 and 9.5 mM, whereas the rat glioma cell line RG2 appeared to be less sensitive with an IC 50 of 14.6 mM ( Table 1) . Trypan blue exclusion demonstrated greater than 90% viability of PA-treated cell cultures. When PA was removed after 48 hours, a clear washout effect was noted in the three cell lines studied (Daoy, U-251MG, and C6) (Fig. 1 right) . The antiproliferative effect of PA was not abrogated by the addition of exogenous glutamine up to 20 mM, 10 times the usual amount of glutamine in tissue-culture media (data not shown).
Cell cycle analysis of Daoy cells treated with 10 mM PA for 2 days showed an accumulation of cells in the G 0 /G 1 phase with an equivalent reduction in the percentage of cells in the S and G 2 /M phases. Prior to treatment, 34.2% of Daoy cells were in the G 0 /G 1 , 55.5% in the S, and 10.3% in the G 2 /M phase. After treatment with PA, 51.9% were in the G 0 /G 1 , 39.9% in the S, and 8.2% in the G 2 /M phase.
Effects of PA on Morphology and Phenotype of Glioma Cell Lines
Phenylacetate induced marked morphological changes in U-251MG cells (Fig. 2) . Prior to treatment, the cells were characterized by spindly, bipolar GFAP-positive processes. After PA treatment for 4 days, cytoplasmic processes were more extensive and complex. The cytoplasmic/nuclear ratio was increased greatly with enlargement of the cell body and elaboration of a radiating stellate array of cytoplasmic processes resembling those of hyperplastic astrocytes. The extent of these morphological changes was dose related. Similar effects were seen in C6 rat glioma cells (Fig. 3) . Most untreated C6 cells were GFAP negative, and in the few positive cells the immunoreactivity localized in the perinuclear region. Although Western blot analysis for GFAP expression in both cell lines failed to show a clear-cut quantitative change after exposure to PA (data not shown), the fraction of C6 glioma cells staining for GFAP increased and filamentous immunoreactivity appeared in the cellular processes. Un- was modified in U-251MG cells by PA treatment (data not shown). When PA treatment was discontinued after 4 days, all morphological changes in U-251MG cells reverted to the pretreatment state within 3 to 5 days.
Effects of PA on the Differentiation State of Medulloblastoma Cell Lines
In short-term cultures of the medulloblastoma cell lines Daoy and D283 MED, growth inhibition by PA was not accompanied by gross morphological changes. Daoy cells expressed both class I and class I HLA immunoreactivity; these phenotypical markers remained unchanged after PA (10 mM) treatment. Neither of the two cell lines expressed synaptophysin and GFAP before or after treatment with PA. Untreated Daoy cells were reactive for EGFR and TGF␣; immunohistochemical staining for EGFR and TGF␣ was not affected by PA treatment.
Expression of Hu is one of the earliest markers of neuronal phenotype in the peripheral nervous system of the quail 24 and one of the earliest markers of neuronal phenotype in the developing CNS of the mouse (GT Manley, unpublished observation). Previous studies of the expression of Hu in human normal and tumor tissue demonstrated that the Hu antigen is highly restricted to the nervous system, small-cell lung cancer tumors, and neuroblastomas. 9 Immunocytochemistry using biotinylated anti-Hu antisera showed Hu antigen expression in D283 MED and BE(2)C cells, whereas Daoy cells and all glioma cell lines were negative. Western blot analysis was used to confirm the immunostaining results (Fig. 4 left) . As previously reported, sera obtained from a typical anti-Hu paraneoplastic patient recognized a group of antigens, with a molecular weight of approximately 35 to 40 kD, from human cortical neurons. 5, 14 No reactivity was observed with serum from a normal individual.
The identity of the Hu antigens recognized in the Western blots of the BE(2)C and D283 MED cell lines was determined by RT-PCR using primers specific for the Hu antigens HuD and HuC. These primers were chosen to amplify a region of these genes that is known to be alternatively spliced. 41 Reverse transcriptase-dependent HuD products of 198, 156, and 117 nucleotides were observed for both BE(2)C and D283 MED (Fig. 4 right, lanes 4 and  5) cell lines. Whereas the alternative splicing pattern of BE(2)C cells appeared to be the same as in normal brain, the pattern of D283 MED cells was different, with the lower two isoforms predominating. No HuD expression was detected in the U-251MG or Daoy cell lines. Expression of HuC was only observed in normal brain. To ensure that viable RNA was obtained from the cell lines that did not express either HuD or HuC, actin primers were used as a positive control.
Whereas D283 MED cells expressed all three NF proteins, Daoy cells proved negative for these neuronal markers. Immunocytochemical analysis of D283 MED cells revealed quantitative changes in NF-M and Hu expression following PA treatment. After exposure to PA (10 mM) for 7 days, NF-M and Hu immunoreactivities were increased. These results were confirmed by Western blot analysis of untreated and PA-treated D283 MED cell homogenates (Fig. 5) . Immunostaining for NF-L revealed similar, but less obvious, changes after PA treatment and NF-H remained unchanged. 
FIG. 3.
Photomicrographs displaying the effect of phenylacetate (PA) treatment on glial fibrillary acidic protein (GFAP) immunocytochemical staining of C6 rat glioma cells. Cells were grown in Eagle's minimal essential medium containing 10% fetal calf serum alone (upper) or with 10 mM PA (lower) for 96 hours, after which the medium was removed and the cells were fixed for 10 minutes in cold acetone. The cells were then incubated with a murine monoclonal antibody (mab) directed against GFAP, and immunoreactivity was detected using the avidin-biotin-peroxidase method. (Reaction with an irrelevant isotype-matched control mAb demonstrated no staining (not shown)). Original magnification ϫ 400.
Effects of PA on the Human Neuroblastoma Differentiation Model BE(2)C
The effects of PA on medulloblastoma cell lines were compared to those on the human neuroblastoma cell line BE(2)C, which represents a well-established bipotential differentiation model for neuronal and glial/schwann cell differentiation, indicated by changes in phenotypical markers such as NF proteins, Hu, and vimentin. In these cells, ATRA induced neuronal differentiation and bromodeoxyuridine (BUdR), which is a glial/schwann cell phenotype. 3, 6, 29, 30 The ATRA-induced neuronal differentiation was associated with an increase in Hu (GT Manley and RA Ross, unpublished data) and NF-M protein 29 expression, and a decrease in vimentin 29 expression. Conversely, PA treatment (10 mM) for 7 days produced a decrease in Hu and NF-M expression and an increase in vimentin expression according to both immunocytochemical and Western blot analysis (Fig. 6) .
Role of TGF␤ in PA-Mediated Growth Inhibition
Recent studies with human glioblastoma A-172 as well as prostatic PC-3 cells showed a selective decrease in TGF␤ 2 after treatment with PA. 34 Incubation of Daoy cells with PA (5 mM) for 6 days led to decreased amounts of TGF␤ 2 in the conditioned medium. The mean optical density (OD) of the control sample was 0.864 with a standard deviation (SD) of 0.240. The mean OD for the PA-treated pair was 0.645 with an SD of 0.049. Conditioned medium from treated cells contained 71 pg/ml and medium conditioned by untreated cells contained 159 pg/ml.
We next tested whether TGF␤ is involved in mediating the growth inhibitory effects of PA on medulloblastoma cells. The addition of exogenous human recombinant TGF␤ 1 or TGF␤ 2 at concentrations ranging from 0.5 pM to 1 nM did not inhibit growth of untreated Daoy cells maintained in MEM containing 0.2% FCS (data not shown). These TGF␤ proteins profoundly inhibited the growth of Mu1Lv cells after a 24-hour exposure with an ID 50 of 2.0 pM. Blocking studies with neutralizing antibodies against TGF␤ 1 or TGF␤ 2 , at concentrations up to 20 g/ml, had no effect on PA-induced inhibition on Daoy and U-251MG cell growth (Fig. 7) . However, these concentrations of antibodies were capable of neutralizing the growth inhibitory effects of exogenous TGF␤ 1 and TGF␤ 2 on Mu1Lv cells.
Discussion
Phenylacetate can induce differentiation of various hematological malignancies 32, 33 as well as solid tumors. 34 Recent studies focusing on primary brain neoplasms documented selective suppression of glioma cell growth in culture and in a rat model. 28, 35 The in vitro and in vivo antitumor activity was noted at PA concentrations found to be nontoxic in children treated with PA for urea cycle disorders. 4 Our current studies confirm and extend these original findings, demonstrating that PA induces cytostasis and differentiation not only in tumors of glial origin but also in medulloblastoma-derived cell lines. in the G 0 /G 1 phase, which was similar to ATRA-induced cell cycle effects previously reported for glioma cell lines. 30 Interestingly, PA showed antiproliferative effects in the U-251MG cell line, which is known to be resistant to ATRA. 48 The rapid onset of growth inhibition by PA is not due to cytotoxicity, because cells resume proliferation and revert to their previous morphology after washout of the agent.
Phenylacetate induced morphological and immunocytochemical changes consistent with astrocytic differentiation in glioma cell lines. Both of the glioma cell lines studied showed marked morphological changes after PA treatment with increased cytoplasmic/nuclear ratios and the formation of GFAP-positive processes. The GFAP immunoreactivity appeared more intense in these newly formed processes; however, Western blot analysis failed to demonstrate a clear quantitative change in GFAP expressions after PA treatment. Previous studies of differentiation agents in glioma cell lines showed similar effects on GFAP expression in U-251MG and C6 cells after treatment with mycophenolic acid. 22 The authors hypothesized that the enhanced immunoreactivity for GFAP without increase in GFAP levels might be due to a modification of existing proteins that alter the organization of assembled GFAP filaments. The discrepancy between immunoblotting and immunocytochemistry may reflect the inability of the blotting technique to detect changes that occur in a subpopulation of cells in a heterogeneous population. Alltransretinoic acid induced phenotypical changes in responsive glioma cell lines similar to those produced by PA. 48 Human glioma cell lines were found to be more sensitive to ATRA compared to rodent cell lines. 48 Interestingly, the least PA-sensitive cell line was also of rodent origin.
In short-term cultures (up to 7 days) of both medulloblastoma cell lines, the group inhibitory effects of PA were not associated with morphological changes and the Daoy cells showed no changes in the cellular expression of the numerous markers tested, including NF proteins, synaptophysin, Hu, TGF␣, EGFR, GFAP, and class I and II HLAs. This temporal dissociation of antiproliferative effects from phenotypical changes has been reported for other differentiation agents. 27, 30 Daoy cells also revealed no morphological changes after treatment with dibutyril cyclic adenosine monophosphate (dBcAMP). 17 The ATRA treatment produced profound growth inhibitory effects in medulloblastoma cell lines without concurrent demonstrable morphological changes, 1 which is in agreement with our data on ATRA studies in medulloblastoma cell lines. 21 Conflicting reports about the clinical relevance of glial or neuronal differentiation in medulloblastoma, as indicated by GFAP and NF protein expression and morphological criteria, 38 reflect an incomplete understanding of the biochemical changes correlated with growth inhibition. In addition, the cell of origin still remains unclear. Phenotypical characterization of medulloblastoma cell lines suggests at least two distinguishable phenotypical patterns, with relative differences in expression of neuronal-or glial-associated antigens. The D283 MED cell line represents a neuronal and the Daoy cell line a nonneural phenotype of medulloblastoma cell lines. 15 Neurofilament protein expression has been used to identify neuronal differentiation. 42 In mature, postmitotic neurons, the NF complex consists of three constituent proteins, termed light (NF-L), medium (NF-M), and heavy (NF-H) chains, based on different molecular weights in denaturing SDS gels. 42 A previously proposed ontogenic schema suggests that the appearance of NF-H correlates with the postmitotic state. 25 Previous studies of NF expression in medulloblastoma cell lines 2 have demonstrated that the CHP707m PNET line expresses only NF-L, suggesting that this cell line reflects an immature state relative to D283 MED cells. The latter cells express all three forms, although in an abnormal manner, 46 suggesting that this defect indicates aberrant NF protein construction and disordered intermediate filament function, which may be a consequence of neoplastic transformation. 15 Disordered NF protein expression was also found in PC12 cells derived from a rat phenochromocytoma. 2, 46 In this nerve growth factor (NGF)-responsive cell line, NGF treatment enhanced the expression of NF-L and NF-M. The ATRA-induced neuronal differentiation of NT2 cells, derived from a human teratocarcinoma, includes induction of expression of all three NF constituents as the cells leave the mitotic cycle and produce neurites. 20, 27 This induction of NF protein expression is accompanied by morphological changes resembling mature neurons 20 and these cells even show action potentials. 47 The Hu antigen is a novel neuronal differentiation antigen not previously studied in medulloblastoma-derived cell lines. This antigen, originally identified by antibodies in patients with paraneoplastic encephalomyelitis/sensory neuropathy, 10, 26, 41 has been shown to be expressed in small-cell lung tumors and neurons. 9, 10, 14 The gene encoding the protein that reacts with anti-Hu antibodies has been sequenced and cloned. 41 The remarkable homology to the Drosophila proteins Elav and Sex-lethal suggests a role for Hu in the maturation of mammalian neurons. It may be a neuron-specific RNA processing protein. 41 The Hu antigen was detectable in both cell lines with features of neuronal differentiation, D283 MED and BE(2)C, and was found to be modulated by PA. This developmental antigen, which is expressed at a very early stage of neuronal commitment, may be an indicator for distinct differentiation pathways and a new marker to better define the differentiation state and subgroups of medulloblastomas. The effect of PA administration on NF protein expression in D283 MED cells was characterized by an increase of NF-M accompanied by an increase in the Hu antigen. Alltransretinoic acid induced opposite effects on NF-M and Hu, suggesting that ATRA does not induce differentiation of D283 MED cells along the neuronal pathway. 21 Expression of Hu did not correlate with synaptophysin expression. None of the medulloblastoma cell lines expressed synaptophysin before or after treatment. This 28-kD glycoprotein, a component of presynaptic vesicles, is characteristic of neuroendocrine cells and neuronally differentiated tumors. 26 Synaptophysin has been reported in a large fraction of medulloblastomas. 8 It is considered a marker of neuronal differentiation, although the prognostic relevance of such expression is unclear.
We studied the effects of PA on the neuroblastoma cell line BE(2)C to compare the response to medulloblastoma cell lines. The cell line BE(2)C represents an intermediate type subclone with features of both neuronal (N)-and glial/schwann (S)-type cells and can be neuronally differentiated by ATRA, or differentiated toward an S-phenotype with BUdR and dBcAMP. 3, 6, 28, 29 During oncogenesis, the appearance of NF proteins coincides with a switch from the expression of vimentin in precursor cells to the expression of NR proteins in nascent neurons derived from these precursors. 43 Phenylacetate and ATRA-induced growth inhibition in BE(2)C cells was accompanied by changes in the expression of NF proteins, Hu, and vimentin, with PA and ATRA inducing opposite effects. In the BE(2)C differentiation model, PA caused differentiation toward the S-phenotype, similar to phenotypical changes reported with BUdR and dBcAMP. 28 The choice of pathway appears cell-line dependent, because D283 MED cells differentiate in a neuronal direction with PA, whereas BE(2)C cells differentiate in a schwann/glial direction. The underlying controls at this switch point are unknown.
The mechanisms by which PA produces its effects are not understood. Although PA could lead to plasma glutamine depletion in humans, an in vitro effect on glutamine metabolism seems unlikely. Phenylacetate is effective in rat and murine systems, in which PA conjugates glycine rather than glutamine 18 and PA's effect on in vitro growth of U-251MG human malignant astrocytoma cells could not be blocked by glutamine supplementation. These findings are in agreement with previous reports on the interaction of glutamine with PA in nonneuroectodermalderived cell lines. 31 Phenylacetate appears to cause hypomethylation of DNA in vitro, 44 but the significance of this observation is unclear. In HL-60 cells, PA treatment is associated with decreased c-myc expression. 31 The TGF␤s (TGF␤ 1 , TGF␤ 2 , and TGF␤ 3 ) are polypeptides that influence the proliferation and differentiation of many cell types. Phenylacetate caused a decrease in TGF␤ 2 mRNA levels of PC-3 prostate carcinoma and A-172 human glioblastoma cells. 34 This family of growth regulatory molecules has been shown to be important to the biology of astrocytoma growth. Numerous cell lines 19 and primary tumor tissue 7, 35 have both been shown to express mRNA for one or more of the three ␤ isoforms. Malignant glioma-derived cell lines demonstrate variable proliferative responses to ␤ in vitro 19 and the responses may correlate with hyperdiploid or aneuploid state and morphological criteria of anaplasia. 19 Transforming growth factor-␤ appears to be a growth inhibitory factor for some astrocytoma cells and a mitogenic factor for others. The molecular basis for the different response is unclear. The role of TGF␤ in the biology of medulloblastoma growth and differentiation has not been studied, in part due to the difficulty in establishing medulloblastoma cell lines and the paucity of cases relative to malignant astrocytomas. Similar to its effects on glial cells, PA downregulates TGF␤ 2 production by Daoy medulloblastoma cells. Our data suggest that changes in the section of TGF␤ 1 and TGF␤ 2 do not mediate the antiproliferative effects of PA. Exogenous TGF␤ 1 and TGF␤ 2 did not block PA-mediated growth inhibition of these cells. The observed change in TGF␤ 2 production might alter tumor growth in vivo by modifying the host's cellular immune response. This question requires further study using immunocompetent animals bearing syngeneic tumors.
Recently clinical trials of PA for the treatment of adults with cancer were begun. Ongoing phase I studies have confirmed that therapeutic levels can be achieved with no significant toxicities and can produce clinical improvement in patients with high-grade gliomas and hormonerefractory prostatic carcinomas. 45 We infer from our in vitro data that PA and related compounds may be useful agents in the treatment of other primary CNS tumors, including medulloblastomas.
